MedTrace Logo

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

NCT00796159 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1723

Last updated 2009-12-23

No results posted yet for this study

Summary

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

Conditions

Interventions

DRUG

Olmesartan medoxomil

olmesartan medoxomil 20 mg and HCTZ 12.5 mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00796159 on ClinicalTrials.gov